Literature DB >> 34633847

Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment.

Sonya Tang Girdwood1,2,3, Min Dong2,3, Peter Tang3,4, Erin Stoneman5, Rhonda Jones5, Toni Yunger5, Austin Ostermeier1,3, Calise Curry1, Melissa Forton1, Traci Hail1, Randi Mullaney1, Patrick Lahni5, Nieko Punt6,7, Jennifer Kaplan3,5, Alexander A Vinks2,3.   

Abstract

Critical illness, including sepsis, causes significant pathophysiologic changes that alter the pharmacokinetics (PK) of antibiotics. Ceftriaxone is one of the most prescribed antibiotics in patients admitted to the pediatric intensive care unit (PICU). We sought to develop population PK models of both total ceftriaxone and free ceftriaxone in children admitted to a single-center PICU using a scavenged opportunistic sampling approach. We tested if the presence of sepsis and phase of illness (before or after 48 h of antibiotic treatment) altered ceftriaxone PK parameters. We performed Monte Carlo simulations to evaluate whether dosing regimens commonly used in PICUs in the United States (50 mg/kg of body weight every 12 h versus 24 h) resulted in adequate antimicrobial coverage. We found that a two-compartment model best described both total and free ceftriaxone concentrations. For free concentrations, the population clearance value is 6.54 L/h/70 kg, central volume is 25.4 L/70 kg, and peripheral volume is 19.6 L/70 kg. For both models, we found that allometric weight scaling, postmenstrual age, creatinine clearance, and daily highest temperature had significant effects on clearance. The presence of sepsis or phase of illness did not have a significant effect on clearance or volume of distribution. Monte Carlo simulations demonstrated that to achieve free concentrations above 1 μg/ml for 100% of the dosing intervals, a dosing regimen of 50 mg/kg every 12 h is recommended for most patients. A continuous infusion could be considered if the target is to maintain free concentrations four times above the MICs (4 μg/ml).

Entities:  

Keywords:  beta-lactams; ceftriaxone; critically ill; pharmacodynamics; pharmacokinetics

Mesh:

Substances:

Year:  2021        PMID: 34633847      PMCID: PMC8765235          DOI: 10.1128/AAC.01427-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  35 in total

1.  Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.

Authors:  Johan W Mouton; Anne Schmitt-Hoffmann; Stuart Shapiro; Norman Nashed; Nieko C Punt
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis and simulation.

Authors:  Satofumi Iida; Takehiko Kawanishi; Masahiro Hayashi
Journal:  J Pharm Pharmacol       Date:  2011-01       Impact factor: 3.765

3.  Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study.

Authors:  Scott L Weiss; Julie C Fitzgerald; John Pappachan; Derek Wheeler; Juan C Jaramillo-Bustamante; Asma Salloo; Sunit C Singhi; Simon Erickson; Jason A Roy; Jenny L Bush; Vinay M Nadkarni; Neal J Thomas
Journal:  Am J Respir Crit Care Med       Date:  2015-05-15       Impact factor: 21.405

4.  PRISM III: an updated Pediatric Risk of Mortality score.

Authors:  M M Pollack; K M Patel; U E Ruttimann
Journal:  Crit Care Med       Date:  1996-05       Impact factor: 7.598

5.  Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies.

Authors:  Tomoyuki Mizuno; Tsuyoshi Fukuda; Chie Emoto; Paula S Mobberley-Schuman; Adrienne M Hammill; Denise M Adams; Alexander A Vinks
Journal:  Pediatr Blood Cancer       Date:  2017-02-16       Impact factor: 3.167

6.  Pharmacokinetics of ceftriaxione, a third-generation cephalosporin, in pediatric patients.

Authors:  Kyoko Fukumoto; Shiori Aida; Tomohiro Oishi; Kazuyuki Ueno
Journal:  Biol Pharm Bull       Date:  2009-07       Impact factor: 2.233

7.  Paediatric index of mortality 3: an updated model for predicting mortality in pediatric intensive care*.

Authors:  Lahn Straney; Archie Clements; Roger C Parslow; Gale Pearson; Frank Shann; Jan Alexander; Anthony Slater
Journal:  Pediatr Crit Care Med       Date:  2013-09       Impact factor: 3.624

Review 8.  Measurement and estimation of GFR in children and adolescents.

Authors:  George J Schwartz; Dana F Work
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-09       Impact factor: 8.237

9.  Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.

Authors:  Juan L Rodríguez-Tudela; Benito Almirante; Dolors Rodríguez-Pardo; Fernando Laguna; J Peter Donnelly; Johan W Mouton; Albert Pahissa; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

10.  Revisiting normal (51)Cr-ethylenediaminetetraacetic acid clearance values in children.

Authors:  A Piepsz; M Tondeur; H Ham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057

View more
  2 in total

1.  Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia.

Authors:  Hideo Kato; Mao Hagihara; Yoshihiko Morikawa; Nobuhiro Asai; Hiroshige Mikamo; Takuya Iwamoto
Journal:  Antibiotics (Basel)       Date:  2022-07-22

2.  Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease.

Authors:  Xiao Chen; Jinglin Wang; Jianger Lan; Xilin Ge; Hong Xu; Yu Zhang; Zhiping Li
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.